PolyPid (PYPD) Stock Forecast, Price Target & Predictions
PYPD Stock Forecast
PolyPid stock forecast is as follows: an average price target of $10.00 (represents a 210.56% upside from PYPD’s last price of $3.22) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
PYPD Price Target
The average price target for PolyPid (PYPD) is $10.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 210.56% upside from PYPD's last price of $3.22.
PYPD Analyst Ratings
According to 4 Wall Street analysts, PolyPid's rating consensus is 'Buy'. The analyst rating breakdown for PYPD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PolyPid Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 04, 2024 | Chase Knickerbocker | Craig-Hallum | $10.00 | $3.33 | 200.30% | 210.56% |
The latest PolyPid stock forecast, released on Nov 04, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $10.00, which represents a 200.30% increase from the stock price at the time of the forecast ($3.33), and a 210.56% increase from PYPD last price ($3.22).
PolyPid Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $10.00 | $10.00 |
| Last Closing Price | $3.22 | $3.22 | $3.22 |
| Upside/Downside | -100.00% | 210.56% | 210.56% |
In the current month, the average price target of PolyPid stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PolyPid's last price of $3.22. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 04, 2024 | Craig-Hallum | Buy | Initialise | |
| Sep 06, 2022 | Raymond James | Outperform | Downgrade | |
| Sep 02, 2022 | Guggenheim | Neutral | Upgrade | |
| Aug 11, 2022 | BMO Capital | Outperform | Outperform | Hold |
PolyPid's last stock rating was published by Craig-Hallum on Nov 04, 2024. The company Initialise its PYPD rating from "null" to "Buy".
PolyPid Financial Forecast
PolyPid Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $2.30M | $1.20M | $300.00K | - | - | - | - | - | - | - | - |
| High Forecast | $2.30M | $1.20M | $300.00K | - | - | - | - | - | - | - | - |
| Low Forecast | $2.30M | $1.20M | $300.00K | - | - | - | - | - | - | - | - |
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
PolyPid's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PYPD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PolyPid EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict PYPD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PolyPid's previous annual EBITDA (undefined) of $NaN.
PolyPid Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-2.67M | $-3.12M | $-3.05M | $-2.74M | $-3.36M | $-3.75M | $-4.39M | $-6.02M | $-7.17M | $-6.38M | $-6.53M |
| High Forecast | $-2.67M | $-3.12M | $-3.05M | $-2.74M | $-3.36M | $-3.75M | $-4.39M | $-6.02M | $-7.17M | $-6.38M | $-6.53M |
| Low Forecast | $-2.67M | $-3.12M | $-3.05M | $-2.74M | $-3.36M | $-3.75M | $-4.39M | $-6.02M | $-7.17M | $-6.38M | $-6.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
PolyPid's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PYPD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PolyPid SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
PolyPid's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PYPD last annual SG&A of $NaN (undefined).
PolyPid EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.42 | $-0.49 | $-0.48 | $-0.43 | $-0.53 | $-0.59 | $-0.69 | $-0.95 | $-1.13 | $-1.00 | $-1.30 |
| High Forecast | $-0.42 | $-0.49 | $-0.48 | $-0.43 | $-0.53 | $-0.59 | $-0.69 | $-0.95 | $-1.13 | $-1.00 | $-1.30 |
| Low Forecast | $-0.42 | $-0.49 | $-0.48 | $-0.43 | $-0.53 | $-0.59 | $-0.69 | $-0.95 | $-1.13 | $-1.00 | $-1.30 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PolyPid's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PYPD previous annual EPS of $NaN (undefined).
PolyPid Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.29 | $14.00 | 4727.59% | Buy |
| KPRX | Kiora Pharmaceuticals | $3.49 | $120.00 | 3338.40% | Buy |
| ELEV | Elevation Oncology | $0.67 | $9.00 | 1243.28% | Buy |
| VRPX | Virpax Pharmaceuticals | $0.34 | $3.00 | 782.35% | |
| PYXS | Pyxis Oncology | $1.63 | $8.50 | 421.47% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| INMB | INmune Bio | $4.98 | $22.00 | 341.77% | Buy |
| PYPD | PolyPid | $2.50 | $10.00 | 300.00% | Buy |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| CUE | Cue Biopharma | $1.06 | $3.00 | 183.02% | Buy |
| ANIX | Anixa Biosciences | $2.74 | $3.50 | 27.74% | Buy |